Disease‐Modifying Osteoarthritis Treatment With Interleukin‐1 Receptor Antagonist Gene Therapy in Small and Large Animal Models
- 10 September 2018
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 70 (11) , 1757-1768
Abstract
Objective: Gene therapy holds great promise for the treatment of osteoarthritis (OA) because a single intraarticular injection can lead to long‐term expression of therapeutic proteins within the joint. This study was undertaken to investigate the use of a helper‐dependent adenovirus (HDAd)–mediated intraarticular gene therapy approach for long‐term expression of interleukin‐1 receptor antagonist (IL‐1Ra) as sustained symptomatic and disease‐modifying therapy for OA.Methods: In mouse models of OA, efficacy of HDAd–IL‐1Ra was evaluated by histologic analysis, micro–computed tomography (micro‐CT), and hot plate analysis. In a horse OA model, safety and efficacy of HDAd–IL‐1Ra were evaluated by blood chemistry, analyses of synovial fluid, synovial membrane, and cartilage, and gross pathology and lameness assessments.Results: In skeletally immature mice, HDAd–IL‐1Ra prevented development of cartilage damage, osteophytes, and synovitis. In skeletally immature and mature mice, treatment with HDAd–interleukin‐1 receptor antagonist post–OA induction resulted in improved—albeit not significantly—cartilage status assessed histologically and significantly increased cartilage volume, cartilage surface, and bone surface covered by cartilage as assessed by micro‐CT. Fewer osteophytes were observed in HDAd–IL‐1Ra–treated skeletally immature mice. Synovitis was not affected in skeletally immature or mature mice. HDAd–IL‐1Ra protected against disease‐induced thermal hyperalgesia in skeletally mature mice. In the horse OA model, HDAd–IL‐1Ra therapy significantly improved lameness parameters, indicating efficient symptomatic treatment. Moreover, macroscopically and histologically assessed cartilage and synovial membrane parameters were significantly improved, suggesting disease‐modifying efficacy.Conclusion: These data from OA models in small and large animals demonstrated safe symptomatic and disease‐modifying treatment with an HDAd‐expressing IL‐1Ra. Furthermore, this study establishes HDAd as a vector for joint gene therapy.Keywords
Funding Information
- Canadian Institutes of Health Research
This publication has 28 references indexed in Scilit:
- Osteoarthritis pain mechanisms: basic studies in animal modelsOsteoarthritis and Cartilage, 2013
- Transgene Expression up to 7 Years in Nonhuman Primates Following Hepatic Transduction with Helper-Dependent Adenoviral VectorsHuman Gene Therapy, 2013
- Role of proinflammatory cytokines in the pathophysiology of osteoarthritisNature Reviews Rheumatology, 2010
- Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled studyArthritis Care & Research, 2009
- The Interleukin 1β Pathway in the Pathogenesis of OsteoarthritisThe Journal of Rheumatology, 2008
- Helper‐dependent adenoviral gene therapy mediates long‐term correction of the clotting defect in the canine hemophilia A modelJournal of Thrombosis and Haemostasis, 2006
- Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vectorProceedings of the National Academy of Sciences, 2005
- Tumour necrosis factor-α, interleukin-1β and interleukin-8 induce persistent mechanical nociceptor hypersensitivityPain, 2002
- Interleukin-1?-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1? and interleukin-18Arthritis & Rheumatism, 1999
- Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.Journal of Clinical Investigation, 1990